Evidence map›Paper›PMID 40802017›Full record

ArticleDiscover oncology2025

Metallothionein 1X is a tumor suppressor gene and inhibits oxidative stress and metastasis in renal cell carcinoma.

Rui Rui, Cong Huang, Yucai Wu, Heng Guo, Yanqing Gong, Xuesong Li, Liqun Zhou, Shiming He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rui RuiDepartment of Urology, Peking University First Hospital, No. 8, Xishiku Street, Xicheng, Beijing, 100034, China.
Cong HuangDepartment of Urology, Peking University First Hospital, No. 8, Xishiku Street, Xicheng, Beijing, 100034, China.
Yucai WuDepartment of Urology, Peking University First Hospital, No. 8, Xishiku Street, Xicheng, Beijing, 100034, China.
Heng GuoDepartment of Urology, Peking University First Hospital, No. 8, Xishiku Street, Xicheng, Beijing, 100034, China.
Yanqing GongDepartment of Urology, Peking University First Hospital, No. 8, Xishiku Street, Xicheng, Beijing, 100034, China.
Xuesong LiDepartment of Urology, Peking University First Hospital, No. 8, Xishiku Street, Xicheng, Beijing, 100034, China. pineneedle@sina.com.
Liqun ZhouDepartment of Urology, Peking University First Hospital, No. 8, Xishiku Street, Xicheng, Beijing, 100034, China. zhoulqmail@sina.com.
Shiming HeDepartment of Urology, Peking University First Hospital, No. 8, Xishiku Street, Xicheng, Beijing, 100034, China. shiminghe@bjmu.edu.cn.

Funding

Capital Health Research and Development of Special Fund 2022-1-4072National Natural Science Foundation of China 82173216
6 · The paper itself

Abstract

Metallothioneins 1X (MT1X) is expressed at low levels in renal cell carcinoma (RCC) and correlates with tumor progression, stage, grade and prognosis, but the mechanism of MT1X's role in renal cell carcinoma is not fully understood at present, and the aim of this study was to investigate the molecular mechanism of MT1X's role in renal cell carcinoma. We used immunofluorescence and flow cytometry to detect intracellular reactive oxygen species (ROS) levels and immunoblotting to detect the expression levels of key proteins of the epithelial-mesenchymal transition (EMT) signaling pathway, transwell assay to assess the cell migration and invasion capacity. It was found that MT1X knockdown significantly upregulated H

Indexed as

Epithelial-mesenchymal transitionMetallothioneins 1XReactive oxygen speciesRenal cell carcinomaTrolox

Identifiers

PMID40802017
PMCPMC12350890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.